$40.9 million cash balance at the end of 2023 expected to provide cash runway into 2H 2025
Completed enrollment of Phase 2 clinical study of EQ101 in alopecia areata: topline data expected in Q2.
Bioniz Therapeutics Receives Orphan Drug Designation from the European Commission for BNZ-1 for Treatment of Cutaneous T-Cell Lymphoma prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.